The evolving landscape of protein kinases in breast cancer: Clinical implications

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 68-76

  Ocaña, Alberto ^a,e   Amir, Eitan ^a   Seruga, Bostjan ^b   Martin, Miguel ^c,f   Pandiella, Atanasio ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c Spanish Breast Cancer Research Group ^*  (Spain)

^d Salamanca Spain   (Spain)

^e Hospital Universitario de Albacete   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Breast cancer; HER2; PI3K mTOR; Protein kinases; Targeted agents

Indexed keywords

AFATINIB; AROMATASE INHIBITOR; BEVACIZUMAB; CABOZANTINIB; CYCLOPHOSPHAMIDE; DALOTUZUMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXELIXIS; EXEMESTANE; LAPATINIB; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROTEIN KINASE; RIDAFOROLIMUS; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84869081293     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.004     Document Type: Review

References (107)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Dillon R.L., White D.E., Muller W.J. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345.
3. Montero J.C., Seoane S., Ocana A., Pandiella A. P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 2011, 30:1059-1071.
4. Alonso A., Sasin J., Bottini N., et al. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
5. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
6. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
7. Cruz J.J., Ocana A., Del Barco E., Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007, 18:421-430.
8. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000, 19:3159-3167.
9. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Cancer 2001, 2:127-137.
10. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
11. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
12. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
13. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60-70.
14. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
15. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
16. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
17. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
18. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
19. Law J.H., Habibi G., Hu K., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008, 68:10238-10246.
20. Nahta R., Yuan L., Zhang B., et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128.
21. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
22. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
23. Serra V., Markman B., Scaltriti M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68:8022-8030.
24. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
25. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
26. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
27. Eichhorn P.J., Gili M., Scaltriti M., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
28. Garcia-Cao I., Song M.S., Hobbs R.M., et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012, 149:49-62.
29. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 2000, 19:5636-5642.
30. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
31. Seoane S., Montero J.C., Ocana A., Pandiella A. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 2010, 102:1432-1446.
32. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
33. Loi S., Haibe-Kains B., Desmedt C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246.
34. Cheang M.C., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
35. Turner N., Pearson A., Sharpe R., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
36. Plaza-Menacho I., Morandi A., Robertson D., et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010, 29:4648-4657.
37. Boulay A., Breuleux M., Stephan C., et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 2008, 68:3743-3751.
38. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 2011, 16:12-19.
39. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
40. Miller T.W., Hennessy B.T., Gonzalez-Angulo A.M., et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413.
41. Crowder R.J., Phommaly C., Tao Y., et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009, 69:3955-3962.
42. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9:153-166.
43. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., Schmidt E.V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
44. Pei X.H., Bai F., Smith M.D., et al. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell 2009, 15:389-401.
45. Hochgrafe F., Zhang L., O'Toole S.A., et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res 2010, 70:9391-9401.
46. Sun T., Aceto N., Meerbrey K.L., et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718.
47. Ponzo M.G., Lesurf R., Petkiewicz S., et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009, 106:12903-12908.
48. Graveel C.R., DeGroot J.D., Su Y., et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009, 106:12909-12914.
49. Lopez-Knowles E., O'Toole S.A., McNeil C.M., et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010, 126:1121-1131.
50. Shah S.P., Roth A., Goya R., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, [Epub ahead of print].
51. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803.
52. Montero J.C., Esparis-Ogando A., Pandiella A., Ocana A. Inhibitor BEZ235 shows antitumor activity against a panel of basal-like cells and potentiates the antitumor activity of taxanes and vinorelbine. San Antonio Breast Cancer Symposium 2010, [Abstract P6-15-19].
53. Hoeflich K.P., O'Brien C., Boyd Z., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15:4649-4664.
54. Mirzoeva O.K., Das D., Heiser L.M., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
55. Ocana A., Amir E., Seruga B., Pandiella A. Do we have to change the way targeted drugs are developed?. J Clin Oncol 2010, 20:420-421.
56. Duncan J.S., Whittle M.C., Nakamura K., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
57. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326.
58. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 1997, 16:1647-1655.
59. Ritter C.A., Perez-Torres M., Rinehart C., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919.
60. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
61. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
62. Zhou B.B., Peyton M., He B., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
63. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
64. Schoeberl B., Pace E.A., Fitzgerald J.B., et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009, ra31.
65. Schoeberl B., Faber A.C., Li D., et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010, 70:2485-2494.
66. Montero J.C., Rodriguez-Barrueco R., Ocana A., Diaz-Rodriguez E., Esparis-Ogando A., Pandiella A. Neuregulins and cancer. Clin Cancer Res 2008, 14:3237-3241.
67. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
68. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004, 64:2343-2346.
69. Gianni L., Pienkowski T., Im Y.-H., et al. Neoadjuvant Pertuzumab (P) and Trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res 2010, 15(Suppl). [Abstract S3-2].
70. Ocana A., Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev 2009, 35:685-691.
71. Gunzer K., Joly F., Delozier T., et al. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 inhibitor, to treatment continuation of letrozole in estrogen receptor (ER-) positive metastatic breast cancer progressing on letrozole. San Antonio Breast Cancer Symposium 2010, [Abstract 4098].
72. Martin M., Bonneterre J., Geyer C.E., et al. A phase 2, randomized, open-label, study of Neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2011, [Abstract S5-7].
73. Hurvitz S., Dirix L., Kocsis J., Gianni L., Lu J., et al. Trastuzumab emtansine (T-DM1) Vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive Metastatic Breast Cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). European Society for Medical Oncology annual congress, Stockholm 2011, [Abstract 5001].
74. Esparis-Ogando A., Ocana A., Rodriguez-Barrueco R., Ferreira L., Borges J., Pandiella A. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 2008, 19:1860-1869.
75. Browne B.C., Crown J., Venkatesan N., et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011, 22:68-73.
76. Ellis M.J., Tao Y., Young O., et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025.
77. Arpino G., Green S.J., Allred D.C., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004, 10:5670-5676.
78. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
79. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
80. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
81. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
82. Sabnis G., Goloubeva O., Jelovac D., Schayowitz A., Brodie A. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007, 13:2751-2757.
83. Bachelot T., Bourgier C., Cropet C., et al. TAMRAD: a GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI). San Antonio Breast Cancer Symposium 2010, [Abstract S1-6].
84. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
85. Di Cosimo S., Bendell J.C., Cervantes-Ruiperez A., et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28(15s). [suppl; abstr 3008].
86. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01234857?term=dalotuzumab+and+breast+cancer&rank=1.
87. Baselga J., Stemmer S., Pego A., Chan A., Goeminne J.-C., Graas M-P K.J., et al. Cetuximab+cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. San Antonio Breast Cancer Symposium 2010, [Abstract PD01-01].
88. Klinakis A., Szabolcs M., Chen G., Xuan S., Hibshoosh H., Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA 2009, 106:2359-2364.
89. Turner N., Lambros M.B., Horlings H.M., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023.
90. Turner N., Tutt A., Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005, 5:388-393.
91. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
92. Tanaka T., Munshi A., Brooks C., Liu J., Hobbs M.L., Meyn R.E. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008, 14:1266-1273.
93. Chinnaiyan P., Huang S., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65:3328-3335.
94. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005, 280:31182-31189.
95. Li L., Wang H., Yang E.S., Arteaga C.L., Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008, 68:9141-9146.
96. Boone J.J., Bhosle J., Tilby M.J., Hartley J.A., Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009, 8:3015-3023.
97. Xiang T., Ohashi A., Huang Y., et al. Negative regulation of AKT activation by BRCA1. Cancer Res 2008, 68:10040-10044.
98. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
99. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
100. Foekens J.A., Peters H.A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001, 61:5407-5414.
101. Ocana A., Amir E., Vera F., Eisenhauer E.A., Tannock I.F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011, 29:254-256.
102. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
103. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
104. Rugo H.S., Stopeck A.T., Joy A.A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29:2459-2465.
105. Martin M., Roche H., Pinter T., et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011, 12:369-376.
106. Barrios C.H., Liu M.C., Lee S.C., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
107. von Minckwitz G., Eidtmann H., Rezai M., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.